Adquey : Acrotech expands nonsteroidal eczema control Adquey On February 12, Acrotech Biopharma won approval for Adquey (difamilast) ointment 1% for adults and pediatric patients aged 2 years and older with mild to moderate atopic dermatitis
This epigenetic modulation affects hundreds of genes involved in: Cell cycle regulation - promoting differentiation and reducing proliferation Healthy inflammatory response - suppressing NF-B and pro-inflammatory cytokines Barrier function - upregulating tight junction proteins Antimicrobial defense - increasing defensin and mucin production Metabolic regulation - enhancing mitochondrial biogenesis A Fine-Tuned Response The concentration-dependent nature of HDAC inhibition adds another layer of sophistication
doi: 10.1111/hel.12428 33 WroblewskiLEPeekRMJr.WilsonKT
Peptide therapy is being explored as a way to support immune balance in people with autoimmune concerns, with the aim of calming an overactive immune response rather than broadly suppressing it
[26] did not show superiority over saline injection in their studies of infiltrative treatment with one and, for Scott's study, even two doses of PRP
GLP-1 (glucagon-like peptide-1) receptor agonists, like semaglutide (brand names Ozempic, Wegovy), have gained immense popularity as effective tools for weight loss and managing type 2 diabetes